Show simple item record

dc.contributor.authorKhairnar, R.
dc.contributor.authorYared, J.A.
dc.contributor.authorOnukwugha, E.
dc.contributor.authorSlejko, J.F.
dc.date.accessioned2019-12-17T20:05:47Z
dc.date.available2019-12-17T20:05:47Z
dc.date.issued2019
dc.identifier.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85076117038&doi=10.1002%2fcam4.2698&partnerID=40&md5=d2b1b5b5082c1adc6e331f1df00d67de
dc.identifier.urihttp://hdl.handle.net/10713/11522
dc.description.abstractThe landscape of treatment for multiple myeloma (MM) has significantly changed over the last decade due to novel agents that have shown superiority in efficacy such as proteasome inhibitors (PIs) and immunomodulatory drugs (IMiDs) over traditional therapies. However, the real-world utilization of these new agents has not been studied well. This study evaluated year-to-year changes in treatment choices in a cohort of patients aged 66 or older in the Surveillance, Epidemiology, and End Results (SEER) registry linked with Medicare claims (SEER-Medicare) data who were diagnosed with MM between 2007 and 2011. We identified 2477 symptomatic newly diagnosed patients who were followed for 6 months or more postdiagnosis and treated with systemic therapies but not with stem cell transplantation. Symptomatic patients were identified by evidence of hypercalcemia, renal failure, anemia, or bone lesions (CRAB criteria). The minimum follow-up was imposed to ensure sufficient data to characterize treatment. Our analysis found that the proportion of treated patients increased from 75% in the 2007 cohort to 79% in the 2011 cohort. The share of PI-based regimens including PI plus alkylating agents, PI plus IMiD, and PI-only increased from 9% to 21%, 3% to 11%, and 16% to 22%, respectively, between 2007 and 2011. These findings translate to the share of PI-based regimens having increased from 28% to 55% and that of IMiDs-based regimens (excluding PI plus IMiD) having decreased from 43% to 27%. In conclusion, while the usage of PIs among elderly MM patients increased significantly replacing IMiD-based regimens (with or without alkylating agents but not with PI) between 2007 and 2011, this significant shift did not increase the proportion of treated patients. Copyright 2019 The Authors.en_US
dc.description.urihttps://doi.org/10.1002/cam4.2698en_US
dc.language.isoen_USen_US
dc.publisherJohn Wiley & Sons Ltd.en_US
dc.relation.ispartofCancer Medicine
dc.subjectelderly patientsen_US
dc.subjectimmunomodulatory drugs (IMiDs)en_US
dc.subjectmultiple myelomaen_US
dc.subjectproteasome inhibitorsen_US
dc.subjectSEER-Medicareen_US
dc.subjectsystemic treatmenten_US
dc.titleUtilization of novel systemic therapies for multiple myeloma: A retrospective study of front-line regimens using the SEER-Medicare dataen_US
dc.typeArticleen_US
dc.identifier.doi10.1002/cam4.2698
dc.identifier.pmid31801177


This item appears in the following Collection(s)

Show simple item record